KASKELA LAW LLC: Shareholder Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.
July 26 2018 - 4:23PM
Business Wire
Kaskela Law LLC announces that a shareholder class action
lawsuit has been filed against ACADIA Pharmaceuticals Inc. (NASDAQ:
ACAD) (“ACADIA” or the “Company”) on behalf of purchasers of the
Company’s securities between April 29, 2016 and July 9,
2018, inclusive (the “Class Period”).
ACADIA investors are encouraged to contact Kaskela Law LLC
(D. Seamus Kaskela, Esq.) at (484) 258 – 1585 or (888) 715 – 1740
for additional information about this action and/or to discuss
their legal rights and options. Investors may also register
their information with the firm at
http://kaskelalaw.com/case/acadia/.
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. One of ACADIA’s
products is NUPLAZID (pimavanserin), which was approved by the U.S.
Food and Drug Administration (“FDA”) in April 2016 for the
treatment of hallucinations and delusions associated with
Parkinson’s disease.
The shareholder class action complaint alleges that ACADIA and
certain other defendants made a series of false and misleading
statements during the Class Period and failed to disclose material
adverse facts to investors about the Company’s business, operations
and prospects. Among other things, the defendants failed to
disclose: (i) that adverse events and safety concerns related to
NUPLAZID threatened the drug’s initial and continuing FDA approval;
and (ii) that ACADIA engaged in business practices likely to
attract regulatory scrutiny. The complaint further alleges that, as
a result of the foregoing, investors purchased ACADIA’s securities
at artificially inflated prices during the Class Period, and
suffered significant investment losses as a result of the
defendants’ conduct.
IMPORTANT DEADLINE: Investors who purchased ACADIA’s
securities during the Class Period may, no
later than September 17, 2018, seek to be appointed as a
lead plaintiff of the investor class. ACADIA investors are
encouraged to contact Kaskela Law LLC for additional information
about this action and/or to discuss their legal rights and options,
or to register their information with the firm at
http://kaskelalaw.com/case/acadia/.
Kaskela Law LLC exclusively represents investors in state and
federal courts throughout the country. For additional information
about Kaskela Law LLC please visit www.kaskelalaw.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180726005975/en/
KASKELA LAW LLCD. Seamus Kaskela, Esq.201 King of Prussia
RoadSuite 650Radnor, PA
19087484-258-1585888-715-1740info@kaskelalaw.comwww.kaskelalaw.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024